bluebird bio Inc
NASDAQ:BLUE
bluebird bio Inc
Net Income (Common)
bluebird bio Inc
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
bluebird bio Inc
NASDAQ:BLUE
|
Net Income (Common)
-$91.2m
|
CAGR 3-Years
48%
|
CAGR 5-Years
30%
|
CAGR 10-Years
-31%
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$4.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$5.7B
|
CAGR 3-Years
258%
|
CAGR 5-Years
1%
|
CAGR 10-Years
6%
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$6.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
25%
|
See Also
What is bluebird bio Inc's Net Income (Common)?
Net Income (Common)
-91.2m
USD
Based on the financial report for Sep 30, 2023, bluebird bio Inc's Net Income (Common) amounts to -91.2m USD.
What is bluebird bio Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-31%
Over the last year, the Net Income (Common) growth was 82%. The average annual Net Income (Common) growth rates for bluebird bio Inc have been 48% over the past three years , 30% over the past five years , and -31% over the past ten years .